The Electrospinning Company was established in 2010 as a spin-out from the UK Science and Technology Research Council (STFC) and is based on the growing Harwell Science and Innovation Campus, near Oxford.
They have developed the expert know-how to design, develop, and manufacture materials for use in regenerative medicine, which seeks to replace or repair damaged or diseased cells or tissues or to simulate the body’s own repair mechanisms.
Electrospun scaffolds are being used to help regenerate bone tissue, human cornea, in tendon surgery, and wound care. They then degrade or are reabsorbed naturally once the patient has healed.
The Newable Venture Limited EIS Roundtable Syndicate Fund first invested in The Electrospinning Company in 2010. So Newable has supported the company from the very beginning.
Newable then was delighted to provide follow-on funding as part of the Series A round, investing alongside Downing Ventures, MidVen, and the Science and Technology Facilities Council.
Ann Kramer, CEO of The Electrospinning Company, said, “the funding will help us maintain the highest possible standards as we grow sales of existing products, increase our customer offer, and develop new biomaterials.”
This is Patient Capital in action.